Objective
The overall objective for this multidisciplinary consortium is to transfer to the clinic our basic discovery that genes can be horizontally transferred to neighbouring cells by uptake of apoptotic cells. Our goal is to develop a therapeutic HIV-1 vaccine based on this technology. Apoptotic cells can be a good antigen delivery system by utilizing the body´s own natural mechanisms for transfer of DNA and proteins to antigen presenting cells (APC). Normally during HIV-1 infection this system is hindered by multiple mechanisms. We therefore envisage using this system during periods of low viral replication achieved by antiretroviral treatment. Hence, we will immunize already infected individuals who have received a limited period of antiretroviral treatmen t with either autologous apoptotic HIV-1 infected cells (AutoCell-HIV) or allogeneic apoptotic HIV-1 pseudovirus containing cells (AlloCell-HIV). The advantages with the present technology are; i)Antigen is targeted to the APC where it is expressed a for long time period. ii)In a mouse model broad cellular and humoral immune responses are generated after immunizations using this strategy. iii)The ¿vector¿ i.e the apoptotic infected cell, is capable of activating dendritic cells leading to stimulation of T cells. iv) The therapy is individualized and contains viral sequences from the patients own virus. v) HIV-1 genes and antigens are transferred to APC in a milieu devoid of viral replication vi) We immunize with apoptotic cells directly and hence do n ot require culturing of dendritic cells, which would be more cumbersome and therefore more difficult to implement in the developing world. We will perform safety and immunogenicity studies in macaques. We will optimize techniques for production of AutoCel l and AlloCell in a Good Manufacturing Practice (GMP) certified Cell Therapy Center. We will produce individualized prototyp e AutoCell compositions and launch a Phase I/II clinical trial.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences medical biotechnology genetic engineering gene therapy
- medical and health sciences basic medicine immunology immunisation
- natural sciences biological sciences genetics DNA
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- medical and health sciences medical biotechnology cells technologies
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP6-2004-LIFESCIHEALTH-5
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
HUDDINGE
Sweden
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.